Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
TSHA
#1815
Taysha Gene Therapies, Inc. Common Stock
4.5
3
+0.44%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+0.44%
Monthly Change
-4.43%
6 month change
+51.51%
Year Change
+177.91%
Previous Close
4.5
1
Open
4.5
3
Bid
Ask
Low
4.5
3
High
4.5
3
Volume
115
Markets
US Stock Market
Healthcare
TSHA
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
News
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin
Taysha doses first patient in pivotal Rett syndrome gene therapy trial
Taysha Gene Therapies stock hits 52-week high at $5.98
Biotech Stocks: Jefferies Names its 6 Top Picks for 2026
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock
Taysha Gene Therapies stock hits 52-week high at 5.51 USD
Goldman Sachs upgrades Taysha Gene Therapies stock rating to Buy
Nagendran Sukumar sells Taysha gene therapies (TSHA) shares for $1.69m
Cantor Fitzgerald maintains Overweight rating on Taysha Gene Therapies stock
Neurogene stock price target raised to $70 from $65 at H.C. Wainwright
Taysha Gene Therapies stock price target raised to $8 at Citizens
Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript